Stock 300841 CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Chengdu Kanghua Biological Products Co., Ltd.

Equities

300841

CNE100003Y57

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 03/07/2024 am IST 		5-day change 1st Jan Change
52.06 CNY +1.22% Intraday chart for Chengdu Kanghua Biological Products Co., Ltd. -1.40% -32.86%
16/06 Certain A Shares of Chengdu Kanghua Biological Products Co., Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2024. CI
29/04 Chengdu Kanghua Biological Products Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 08 May 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Chengdu Kanghua Biological Products Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 08 May 2024
CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Chengdu Kanghua Biological Products Co., Ltd. Proposes Final Cash Dividend for the Year 2023
CI
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on January 23, 2024.
CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Chengdu Kanghua Biological Products Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
CI
Chengdu Kanghua Biological Products Co., Ltd. authorizes a Buyback Plan.
CI
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax
MT
Hillevax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
CI
Jinan Kangyue Qiming Investment Partnership (Limited Partnership) completed the acquisition of 7.4% stake in Chengdu Kanghua Biological Products Co., Ltd. from Aokang Group Co., Ltd. and Wang Zhentao.
CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Jinan Kangyue Qiming Investment Partnership (Limited Partnership) agreed to acquire 7.4% stake in Chengdu Kanghua Biological Products Co., Ltd. from Aokang Group Co., Ltd. and Wang Zhentao for approximately CNY550 million.
CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chengdu Kanghua Biological Products Co., Ltd. Approves Cash Dividend for 2022, Payable on 24 May 2023
CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Chengdu Kanghua Biological Products Co., Ltd. Proposes Final Cash Dividend for the Year of 2022
CI
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 29, 2021.
CI
Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback announced on October 29, 2021, has expired with 901,775 shares, representing 0.67% for CNY 123.10 million.
CI
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 29, 2021.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300841 Stock
  4. News Chengdu Kanghua Biological Products Co., Ltd.
  5. Highlights